RT Journal Article
SR Electronic
T1 P169 Long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis: pooled analysis of 4 clinical trials
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP A175
OP A176
DO 10.1136/thoraxjnl-2016-209333.312
VO 71
IS Suppl 3
A1 Noble, PW
A1 Albera, C
A1 Lancaster, L
A1 Hormel, P
A1 Hulter, H
A1 Costabel, U
YR 2016
UL http://thorax.bmj.com/content/71/Suppl_3/A175.2.abstract
AB Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible disease that requires long-term management. The objective of this study was to assess the long-term safety of pirfenidone from a pooled analysis of 4 clinical studies.Methods All patients who received pirfenidone (2403 mg/d) in the Phase 3 studies (ASCEND/CAPACITY) and/or the long-term extension study (RECAP) were included in this analysis. Safety outcomes were assessed during the period from the first dose until 28 days after the last dose of pirfenidone in either study. Analyses included the final data from the Phase 3 studies and RECAP (data cut, June 30, 2015).Results The pooled population included 1216 patients with a cumulative total exposure of 3366 patient-exposure years. Median pirfenidone exposure was 25.9 months (range, 0–105 months), with a mean dose of 2306 mg/d. 99% of patients reported ≥1 treatment-emergent adverse event (TEAE). 57% of patients reported a serious TEAE (0.51 per patient-exposure year [PPEY]), the most common being IPF (21.5%) and pneumonia (9.3%; Table). TEAEs led to discontinuation in 45% of patients (0.17 PPEY), the most common being IPF (15.9%), rash (1.6%) and nausea (1.6%). Median survival on treatment (or ≤28 days after discontinuation of pirfenidone) was 82.6 months.Conclusions The safety findings from this pooled analysis are consistent with the known safety profile of pirfenidone and the underlying disease of IPF.View this table:Abstract P169 Table 1 Summary of TEAEsa